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INTRODUCTION
Transplantation of hematopoietic stem cells from the
blood or bone marrow of allogeneic donors after intensive
cytotoxic treatment is now standard practice for a variety of
hematologic malignancies. Because recipients are severe l y
i m m u n o c o m p romised, it has been customary to use vary i n g
d e g rees of isolation to prevent acquisition of potentially
l i f e - t h reatening infection [1-15]. Such protective measure s
range from simple barrier nursing to units equipped with
high energy particulate air (HEPA) filters and/or laminar
air flow (LAF). Despite the lack of controlled studies show-
ing a survival benefit of isolation in patients with hemato-
logic malignancy, some centers remain cautious about mov-
ing towards delivering transplants in the outpatient setting.
In 1992, we re p o rted our pre l i m i n a ry experience with 50
adult patients treated without isolation, and we felt it was
timely to reassess the safety of this policy [16]. The curre n t
re p o rt is an update limited to patients with leukemia and
myelodysplasia to include a pediatric population and to
allow some comparison with published data according to
known risk factors.
PATIENTS AND METHODS
Pa t i e n t s
Two hundred and eighty-eight consecutive patients with
c h ronic myelogenous leukemia (CML), acute lymphoblastic
leukemia (ALL), acute myelogenous leukemia (AML), and/or
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ABSTRACT
Although it is common practice to use some form of isolation to protect allogeneic stem cell transplant patients fro m
infection, the necessity for these practices in all environments has not been demonstrated. The current study evalu-
ated patterns of infection and 100-day transplant-related mortality in 288 patients with myelodysplasia and leukemia
transplanted without isolation. Patients were allowed out of hospital at any time within constraints of the medication
schedule. Fever, foci of infection, and positive cultures within 28 days and death within 100 days because of the trans-
plant pro c e d u re were re c o rd e d . F e v e r o c c u rred in 57% of patients, and 10% had a clinical or radiographic focus of
infection. Most infections were apparently endogenous; blood cultures from 24% of recipients grew organisms,
87% of which were gram-positive bacteria. Four patients (1%) died with a s p e rg i l l u s infection in circumstances indi-
cating that isolation would not have been helpful. Twenty percent of patients remained without evidence of infection
t h roughout. Tr a n s p l a n t - related mortality at 100 days was 1% for 108 patients with early leukemia receiving trans-
plants from matched siblings. For patients at higher risk, by virtue of donor and/or disease status, mortality was 21%.
These fig u res compare favorably with those re p o rted to the International Bone Marrow Transplant Registry, the
majority of patients having been subjected to some form of isolation. We conclude that allogeneic stem cell trans-
plantation can be safely perf o rmed in some environments without confining patients continuously to the hospital.
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myelodysplasia (MDS) were treated between January 1988
and April 1998. All received a first transplant with unmanipu-
lated (ie, not T-cell–depleted) cells. The analysis was limited
to these diagnoses for several reasons. Seventy to 80% of allo-
transplants are perf o rmed for these disorders [17]. We wished
to have disease subgroups large enough to analyze for which
comparable data are available in the literature. Table 1 sum-
marizes the pretransplant characteristics of the patients.
DNA-based typing for class II antigens only became available
during the study period, so mismatching is based on sero l o g i-
cal typing only. The alternative donor (AD) group comprises
patients mismatched with their related donors by up to
1 human leukocyte antigen (HLA) -A, -B, or Dr antigen in
the graft-versus-host direction and those receiving unre l a t e d
donor transplants. For analysis of nonrelapse or tre a t m e n t -
related mortality (TRM), patients were divided into gro u p s
a c c o rding to 3 factors influencing outcome, namely disease
status, age, and matched sibling donor (MSD) or AD. Good
risk patients had acute leukemia in any remission or CML in
first chronic phase; all others were considered high risk.
Treatment of Recipients
Foothills Hospital and Alberta Childre n ’s Hospital are
t e rt i a ry re f e rral centers treating patients from Alberta and
s u rrounding provinces, including those with HIV and other
infectious diseases. The Foothills Hospital in part i c u l a r
u n d e rgoes frequent re c o n s t ruction. Patients were nursed in
s t a n d a rd single rooms in a general adult or pediatric hema-
tology/oncology unit. Dietary restrictions were limited to
the elimination of unwashed fruit or vegetables, avoidance of
foods with high bacterial content (eg, certain milk pro d u c t s )
and insistence on thorough cooking. Visitors were instru c t e d
to wash their hands care f u l l y. Otherwise, patients were fre e
to leave the room and the hospital within the constraints of
the treatment regimen, although they retained a hospital bed
at least until the second week after transplant. Avoidance of
c rowds and individuals with active infections was encour-
aged, and patients wore masks when entering and leaving the
hospital when re c o n s t ruction was taking place. No changes
in home environment, including pets, were re c o m m e n d e d ,
but patients were advised against renovations. 
Most patients received acyclovir 5 mg/kg intravenously
twice a day or 400 mg by mouth 4 times daily (3 were given a
higher dose of 500 mg/m2 intravenously every 8 hours).
Adults treated before 1993 and all children were given an
adult equivalent dose of trimethoprim 160 mg/sulfamethoxa-
zole 800 mg (cotrimoxazole) twice a day intravenously or by
mouth. After 1993, 138 adult patients received cotrimoxazo-
let twice a day for pneumocystis and cipro floxacin 500 mg by
mouth twice a day for bacterial prophylaxis. Forty-eight chil-
Table 1. Patient Characteristics*
Number (Percentage)
Donor MSD Unrelated & related mismatched AD Total
Total number 176 (100) 112 (100) 288 (100)
Age <18 years/ ≥18 years 25 (14)/151 (86) 34 (30)/78 (70) 59 (20)/229 (80)
Male/female 107 (61)/69 (39) 60 (54)/72 (46) 167 (58)/141 (42)
Diagnosis
AML CR1 37 (21) 6 (5) 43 (15)
AML CR2 5 (3) 4 (4) 9 (3)
AML+ or MDS not in remission 47 (27) 29 (26) 76 (26)
ALL CR1 10 (6) 6 (5) 16 (6)
ALL CR ≥2 16 (9) 18 (16) 34 (12)
ALL not in remission 13 (7) 15 (13) 28 (10)
CML first chronic phase 40 (23) 16 (14) 56 (19)
CML other 8 (5) 18 (16) 26 (9)
Total good risk 108 (61) 50 (45) 158 (55)
Total high risk 68 (39) 62 (6) 130 (45)
Conditioning 
VP16 60 mg/kg
+ TBI 1200 cGy 54 (31) 7 (6) 63 (22)
+ TBI 500 cGy 2 (1) 2 (0.7)
Cyclophosphamide (Cy) 120 mg/kg
+ Busulfan 16 mg/kg 112 (64) 22 (20) 134 (49)
+ TBI 500 cGy 2 (1) (0.7)
+ TBI 1200 cGy 3 (2) 33 (29) 36 (13)
+ Other 1 (0.6) 3 (3) 4 (1)
Cy 180 mg/kg
+ TBI 1200 cGy 2 (1) 45 (40) 47 (16)
+ Other 2 (2) 2 (0.7)
ATG included 1 (0.6) 46 (36) 47 (16)
Stem cell source
Bone marrow/blood 63 (36)/113 (64) 99 (88)/13 (12) 162 (56)/126 (44)
*MSD indicates matched sibling donor; AD, alternative donor; AML, acute myelogenous leukemia; CR, complete remission; ALL, acute lymphoblastic leukemia;
MDS, myelodysplasia; CML, chronic myelogenous leukemia; TBI, total body irradiation.
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d ren and 44 adults received immunoglobulin intravenously
200 mg/kg 3 times a day, then weekly for 3 months as part of
a study that was discontinued after no benefit for immuno-
globulin was shown (Russell et al., unpublished data). All
patients were transfused with products from cytomegaloviru s
(CMV)-antibody-negative donors. Single donor platelets
w e re given to maintain counts >20 3 1 09/L, and red cells
w e re given to keep hemoglobin levels >80 g/L. Growth fac-
tors were not given ro u t i n e l y, apart from 22 patients with
ALL involved in a study of granulocyte colony-stimulating
f a c t o r. Systemic antifungal prophylaxis was not employed.
After engraftment, 58 AD transplant recipients received pro-
phylactic ganciclovir 5 mg/kg intravenously 3 times weekly.
The acute graft-versus-host disease (GVHD) pro p h y-
laxis protocol comprised cyclosporin A orally or intra-
venously twice daily to maintain blood levels between
250 and 400 mmol/L. Methotrexate was given in doses of
15 mg/m2 intravenously on day 1 and 10mg/m2 on days 3, 6,
and 11. Folinic acid 5 mg intravenously or by mouth was
started 24 hours after each dose of methotrexate and contin-
ued every 6 hours until 12 hours before the next dose [18].
Criteria for commencing intravenous antibiotics
included a single temperature reading above 38.5°C, fever
above 38.0°C for 4 hours, and/or a clinical focus of infec-
tion. Blood cultures were done twice weekly and as clinically
indicated. Other investigations, including bacterial and viral
culture, were done if there was clinical suspicion of infection
at a particular site.
Infections suspected or proven within 28 days of trans-
plant were re c o rded because this time period covers the neu-
t ropenic phase for most patients who engraft. Criteria for
diagnosis of infection included 1 or more of the following:
f e v e r, a clinical or radiologic focus, or positive cultures. The
latter did not need to be accompanied by other evidence;
thus there may have been a tendency to overdiagnose conta-
minated specimens as infection. Reactivation of herpes
v i ruses and the presence of Clostridium diffic i l e in the stool
w e re not included.
E n g r a f t m e n t
Daily blood counts were perf o rmed until discharg e .
Granulocyte engraftment was defined as a count of >0.5 3
1 09/L (graft failure indicated failure to reach this level by
day 28). For patients dying without engraftment beyond
28 days, graft failure was given as the primary cause of death.
Statistical Anal y s i s
The estimate of TRM at 100 days was used as a major
endpoint. The Kaplan-Maier method was employed, and
patients were censored at death with active leukemia. The
log-rank test was used to compare outcomes. Analysis was
performed on a Macintosh computer using GraphPad Prism
software (GraphPad, San Diego, California, USA).
RESULTS
I n f ection 
Table 2 summarizes the evidence of infection, and Tables 3
to 5 give details of sites of infection and organisms culture d .
In summary, 57% of recipients became febrile. Seventy-two
blood cultures from 69 patients (24%) were positive (Table 3).
Of these, gram-positive organisms were responsible in 87%,
m o re than half of which were Staphylococcus epiderm i d i s. Ye a s t s
w e re grown in 7% but did not contribute to 100-day TRM.
Of 24 urine cultures from 21 patients (7%), 6 grew S. epider -
m i d i s and 6 grew yeast, with a variety of other org a n i s m s
accounting for the remainder (see Table 4). Thirty patients
(10%) had a clinical or radiological focus of infection other
than blood or urine (Table 5). A s p e rg i l l u s was detected in 1 of
these, entero v i ruses in 3, C a n d i d a albicans in 1, and S t a p h y l o c o c -
cus aure u s in 1. No cause for fever was identified in 128 (44%)
of patients, and 20% remained without fever or other evi-
dence of infection thro u g h o u t .
Table 2. Summary of Infections Within 28 Days of SCT*
Evidence of infection Number of patients (%)
Fever 165 (57)
Positive culture and/or focal infection 102 (35)
Fever of unknown origin 128 (44)
No evidence of infection 58 (20)
*SCT indicates stem cell transplantation.
Ta b le 3. Details of 72 Positive Blood Cultures from 69 Patients (24% of Total)
Organism Number (%)
Gram positive bacteria




Enterococcus spp 4 (5)
Other 9 (13)
Gram negative bacteria 4(5)
Escherichia coli 2 (3)
Enterobacter cloacae 2 (3)
Yeast 7(10)
Candida albicans 4 (5)
Candida glabrata 1 (1)
Candida parapsilosis 2 (3)
Total 72 (100)
Ta b le 4. Details of 24 Positive Urine Cultures from 21 Patients (7% of Total)
Organism Number (%)
Yeast
Candida albicans 6 (25)
Candida glabrata 1 (4)
Candida parapsilosis 1 (4)
Unknown 3 (13)
Staphylococcus epidermidis 6 (25)
Streptococcus spp 2 (8)
Citrobacter freundii 2 (8)
Enterococcus 1 (4)
Escherichia coli 1 (4)
Klebsiella pneumoniae 1 (4)
Total 24 (100)
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N o n re l a pse Mor t a l i t y
T h i rty-eight patients, 13% of the total, died without
leukemia within 100 days of transplant (Table 6). Identifi-
able organisms were felt to cause or contribute to death in
9 cases (24%). These included CMV in 4 patients and
influenza A in 1. A s p e rg i l l u s was identified ante-mortem in
1 patient, a 36-year-old woman with GVHD after a mis-
matched unrelated donor transplant. Two others had the
o rganism identified at autopsy after a prolonged stay in
intensive care. A final patient with graft failure after AD
transplant was found to have intracranial a s p e rg i l l u s a t
autopsy in the site of a previous mucor infection.
N o n relapse mortality in the subgroups according to dis-
ease, age, and donor are shown in Table 7. For good-risk
patients, the effect of age was significant only after AD trans-
plants (5 ± 5% for children vs. 24 ± 8% for adults, P = .04).
M o rtality was lower for adults with good-risk disease
after MSD (1 ± 1%) than after AD transplants (24 ± 8%, 
P < .0001). All but 1 of the pediatric deaths were after AD
transplants for advanced disease; numbers were insufficient to
d e t e rmine the significance of this observation. For poor- r i s k
disease, neither age nor donor influenced outcome, again per-
haps due to small numbers of children. Likewise, AD transplant
outcomes were unaffected by age or disease stage. There was no
s i g n i ficant change in mortality of any subgroup with time.
DISCUSSION
Although in this program only about one quarter of
“inpatient” days are spent outside the hospital, about 80% of
these are during the neutropenic phase. About one quarter of
patients are discharged before engraftment [19]. This rather
liberal policy is cheaper and seems more acceptable to
patients and staff than isolation regimens. Clearly, however,
the practice can only be justified if patient safety is not com-
p romised. The question at issue is whether, given patterns of
infection in a given institution, strict isolation pro c e d u res add
anything to other widely practiced prophylactic measure s .
This study confirms our previous observations concern-
ing sources of infection. Most infections appear to be
endogenous, with mainly gram-positive organisms gro w n
from the blood of about one quarter of patients. The clinical
significance of some cultures of organisms such as S. epider -
midis is unknown, and we may be overdiagnosing infection
by recording them as significant. This tendency will proba-
bly not influence the conclusions because infections with
these organisms are usually treatable and relatively mild.
Gram-negative organisms and yeasts, both C. albicans a n d
non-albicans species, were relatively infrequent and did not
contribute to TRM at 100 days. The death from influenza
occurred over a month after engraftment. The findings are
consistent with other reports more than the last decade and
suggest that most events are unlikely to be affected by isola-
tion [20-22].
The most likely benefit of isolation would be its effect
on the acquisition of airborne pathogens such as aspergillus.
Invasive infections from such organisms carry a high mor-
tality, usually more than 80% [13,14,23]. Four patients (1%)
died with evidence of a s p e rg i l l u s infection. Two had long
stays in the intensive care unit, where strict isolation is
Table 5. Details for 30 Patients (10% of Total) With 1 or More Focus of
Infection*
Number and Organisms
Clinical and/or Percentage (Number of 
Radiological Focus of Patients Positive Cultures)
Upper respiratory tract 2 (6) RSV (2)
Lung 10 (29) Aspergillus (1)
Skin (cellulitis,
including catheter site) 9 (26)
Sinus 6 (18)
Lymph node 1 (3) Candida albicans
Meninges 1 (3) Staphylococcus aureus
Parotid 1 (3)
Gastrointestinal 4 (12) Rotavirus (3);
other enterovirus (1)
Total 34 (100)
*RSV indicates respiratory syncytial virus.
Table 6. Causes of Nonrelapse Death Before Day 100*
Number and
Primary Cause Percentage of Deaths Comments
Acute graft-versus-host disease 13 (34) Cytomegalovirus (1), aspergillus at autopsy after ICU stay (1)
Graft failure 6 (16) 3 after boost or second transplant; 
1 aspergillus at autopsy at site of previous mucor infection
Adult respiratory distress syndrome (idiopathic) 5 (13)
Cytomegalovirus 3 (13)
Multiple organ dysfunction 3 (13)
Aspergillus 2 (5) 1 diagnosed antemortem; 1 at autopsy after ICU stay
Veno-occlusive disease 1 (3)
Pneumonia 1 (3)
Hemolytic uremic syndrome 1 (3)
Influenza A 1 (3)
Bronchiolitis obliterans 1 (3)
Central nervous system lesion 1 (3)
Total 38 (100)
*ICU indicates intensive care unit. 
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d i ff icult and where infection was superimposed on multi-
organ failure. One may already have been colonized, and the
fourth was at high risk from GVHD and immune suppres-
sion and developed clinical signs more than 2 months
p o s ttransplant. It is doubtful whether isolation would have
p revented any of these deaths. Although invasive filamen-
tous fungi are underdiagnosed without autopsy, the severity
of the primary causes of death in our other patients, possibly
excepting 1 with an undiagnosed central nervous system
lesion, were such that additional infection would pro b a b l y
not have affected the outcome.
Most of the factors leading to improved early outcomes
after stem cell transplantation, such as GVHD prophylaxis,
w e re standard practice by the late 1980s [24]. We have no
indication that differences in infection prevention (eg, oral
antibiotics or immunoglobulin) influenced outcome in our
patients. Acute GVHD prophylaxis was identical for all.
Although prophylactic ganciclovir may influence CMV dis-
ease, in this context CMV is largely endogenous and
unlikely to be directly affected by isolation practices. Like-
wise, our experience indicates no effect of stem cell source
on early mortality [25,26].
Nonrelapse mortality at 100 days is commonly used as
an indicator of regimen-related toxicity and supportive care
early after transplant. In the present context, the expense of
isolation could probably only be justified if it influenced
m o rt a l i t y. Any comparison of outcomes must make allowance
for the influence of age, donor, and disease stage. Good-risk
patients are probably a more homogeneous group, with out-
comes more comparable between studies than those with
m o re advanced leukemia. Data for 1996-1997 from the
I n t e rnational Bone Marrow Transplant Registry (IBMTR)
give 100-day mortalities of 10% to 20% for patients with
good-risk leukemia transplanted from HLA-identical sib-
lings [17]. A figure of 1% for 108 transplants for such
patients compares quite favorably and indicates that no ben-
efit from isolation would be detectable using this criterion.
The trend to higher TRM for patients with advanced dis-
ease and those receiving AD transplants is expected. The
IBMTR gives figures of 30% to 40% for poor-risk patients,
even after MSD transplants, although a few would be
leukemic deaths [17]. Although some deaths from GVHD
and graft failure might have been influenced by our prac-
tices, the indications seem insufficient to justify a change,
even for the patients at higher risk.
Documentation of the benefits or otherwise of pro t e c t i v e
isolation remains relatively scarc e . A number of re p o rts fro m
single centers indicate a reduction in acquisition of infection
as isolation pro c e d u res are intensified [1-6]. H o w e v e r, with
the exception of 1 study of aplastic anemia patients, there
seems to have been little impact on survival [8]. A more re c e n t
analysis of more than 5000 patients from the IBMTR indi-
cated an early survival benefit for leukemia patients treated in
LAF- and/or HEPA - f i l t e red units in contrast to “conven-
tional” isolation in single rooms [9]. A single cause for the
lower 100-day TRM was not identified, although re c i p i e n t s
of AD transplants had lower rates of fungal pneumonia. The
impact of the stricter isolation was apparent only within the
first 100 days but was re flected in improved survival at 1 year.
Recipients of AD transplants seemed to benefit more fro m
isolation. The authors of the IBMTR re p o rt conceded that
the HEPA/LAF isolation could be an indirect indicator of
u n i d e n t i fied aspects of supportive care. Outcomes were better
at higher latitudes, an effect that could perhaps be enhanced
in Calgary by a relatively cold, dry climate and altitude of
m o re than 1000 meters. However, the IBMTR study (whose
isolation criteria excluded our patients) observed the effect of
enhanced isolation at all latitudes. If “conventional” isolation
is inferior to more stringent measures, it is natural to infer
that no isolation would be even worse. 
The IBMTR publication is likely to increase the reluc-
tance of transplant centers to abandon isolation if they have
not already done so. There may also be institutions experi-
encing high infection rates with airborne pathogens for
whom this would be unwise. We can only maintain that our
policy is feasible in some centers, is cheaper in the short run,
and is certainly more tolerable for both patients and staff.
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